Skip to main content

Therapeutischer Einsatz von Cannabinoiden bei neurologischen Erkrankungen

Zusammenfassung

Der folgende Beitrag gibt eine Übersicht über therapeutische Einsatzmöglichkeiten von Cannabinoiden in der Neurologie. Dabei werden für die multiple Sklerose, die spastischen Querschnittsyndrome, die Epilepsie, die Bewegungsstörungen und die Neuroprotektion bei Schädel-Hirn-Trauma oder zerebraler Ischämie jeweils die Ergebnisse präklinischer Untersuchungen dargestellt, welche eine rationale Grundlage für eine klinische Erprobung von Cannabinoiden bilden. Anschließend werden die aktuell verfügbaren klinischen Daten (Fallberichte, offene und kontrollierte Studien) vorgestellt und kritisch bewertet. Insgesamt kann danach der systematische therapeutische Einsatz von Cannabinoiden auf der Basis der vorliegenden klinischen Daten bei keinem der genannten neurologischen Syndrome empfohlen werden. Für die Zukunft sind größere kontrollierte Studien erforderlich.

Abstract

This review gives insight into the potential therapeutical role of cannabinoids in neurology. Preclinical data are presented which could give a rationale for the clinical use of cannabinoids in the fields of multiple sclerosis, spasticity, epilepsy, movement disorders, and neuroprotection after traumatic head injury or ischemic stroke. Besides, clinical data (case reports, open-label and randomised controlled studies) dealing with the therapeutical use of cannabinoids in these fields are reported and discussed. At present, clinical data are insufficient to recommend the use of cannabinoids in any neurological disease as standard therapy. Several questions still have to be answered (which cannabinoid? which way of administration? stimulation of endogenous cannabinoids? separation between desired and undesired effects?), and controlled studies are still needed to clarify the potential therapeutical role of cannabinoids in neurology.

This is a preview of subscription content, access via your institution.

Literatur

  1. 1.

    Achiron A, Miron S, Lavie V, Margalit R, Biegon A (2000) Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis. J Neuroimmunol 102:26–31

  2. 2.

    Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffman JW, Layward L (2000) Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 404:84–87

  3. 3.

    Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A, Khanolkar A, Layward L, Fezza F, Bisogno T, Di Marzo V (2001) Endocannabinoids control spasticity in a multiple sclerosis model. Faseb J 15:300–302

  4. 4.

    Belayev L, Bar-Joseph A, Adamchik J, Biegon A (1995) HU-211, a nonpsychotropic cannabinoid, improves neurological signs and reduces brain damage after severe forebrain ischemia in rats. Mol Chem Neuropathol 25:19–33

  5. 5.

    Brenneisen R, Egli A, Elsohly MA, Henn V, Spiess Y (1996) The effect of orally and rectally administered delta 9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. Int J Clin Pharmacol Ther 34:446–452

  6. 6.

    Clifford DB (1983) Tetrahydrocannabinol for tremor in multiple sclerosis. Ann Neurol 13:669–671

  7. 7.

    Consroe P, Laguna J, Allender J, Snider S, Stern L, Sandyk R, Kennedy K, Schram K (1991) Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol Biochem Behav 40:701–708

  8. 8.

    Consroe P, Musty R, Rein J, Tillery W, Pertwee R (1997) The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 38:44–48

  9. 9.

    Consroe P, Sandyk R (1992) Potential role of cannabinoids for therapy of neurological disorders. In: Murphy L, Bartke A (eds) Marijuana/cannabinoids: neurobiology and neurophysiology. CRC Press, Ann Arbor, MI, pp 459–524

  10. 10.

    Consroe P, Sandyk R, Snider SR (1986) Open label evaluation of cannabidiol in dystonic movement disorders. Int J Neurosci 30:277–282

  11. 11.

    Consroe PF, Wood GC, Buchsbaum H (1975) Anticonvulsant nature of marihuana smoking. JAMA 234:306–307

  12. 12.

    Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimentel C, Gagliardi R, Sanvito WL, Lander N, Mechoulam R (1980) Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 21:175–185

  13. 13.

    Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946–1949

  14. 14.

    Dunn M, Davis R (1974) The perceived effects of marijuana on spinal cord injured males. Paraplegia 12:175

  15. 15.

    Ellison JM, Gelwan E, Ogletree J (1990) Complex partial seizure symptoms affected by marijuana abuse. J Clin Psychiatry 51:439–440

  16. 16.

    Feigenbaum JJ, Bergmann F, Richmond SA, Mechoulam R, Nadler V, Kloog Y, Sokolovsky M (1989) Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker. Proc Natl Acad Sci U S A 86:9584–9587

  17. 17.

    Fox SH, Kellett M, Moore AP, Crossman AR, Brotchie JM (2002) Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Mov Disord 17:145–149

  18. 18.

    Gaoni Y, Mechoulam R (1964) Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 86:1646–1647

  19. 19.

    Glass M, Brotchie JM, Maneuf YP (1997) Modulation of neurotransmission by cannabinoids in the basal ganglia. Eur J Neurosci 9:199–203

  20. 20.

    Gordon E, Devinsky O (2001) Alcohol and marijuana: effects on epilepsy and use by patients with epilepsy. Epilepsia 42:1266–1272

  21. 21.

    Greenberg HS, Werness SA, Pugh JE, Andrus RO, Anderson DJ, Domino EF (1994) Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Clin Pharmacol Ther 55:324–328

  22. 22.

    Hanus L, Gopher A, Almog S, Mechoulam R (1993) Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J Med Chem 36:3032–3034

  23. 23.

    Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC (1990) Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 87:1932–1936

  24. 24.

    Karler R, Calder LD, Turkanis SA (1986) Prolonged CNS hyperexcitability in mice after a single exposure to delta-9-tetrahydrocannabinol. Neuropharmacology 25:441–446

  25. 25.

    Keeler MH, Reifler CB (1967) Grand mal convulsions subsequent to marijuana use. Case report. Dis Nerv Syst 28:474–475

  26. 26.

    Killestein J, Hoogervorst EL, Reif M, Kalkers NF, Van Loenen AC, Staats PG, Gorter RW, Uitdehaag BM, Polman CH (2002) Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 58:1404–1407

  27. 27.

    Knoller N, Levi L, Shoshan I, Reichenthal E, Razon N, Rappaport ZH, Biegon A (2002) Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial. Crit Care Med 30:548–554

  28. 28.

    Kogel RW, Johnson PB, Chintam R, Robinson CJ, Nemchausky BA (1995) Treatment of spasticity in spinal cord injury with dronabinol, a tetrahydrocannabinol derivative. Am J Ther 2:799–805

  29. 29.

    Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452

  30. 30.

    Leker RR, Shohami E, Abramsky O, Ovadia H (1999) Dexanabinol, a novel neuroprotective drug in experimental focal cerebral ischemia. J Neurol Sci 162:114–119

  31. 31.

    Lyman WD, Sonett JR, Brosnan CF, Elkin R, Bornstein MB (1989) Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. J Neuroimmunol 23:73–81

  32. 32.

    Mailleux P, Parmentier M, Vanderhaeghen JJ (1992) Distribution of cannabinoid receptor messenger RNA in the human brain: an in situ hybridization histochemistry with oligonucleotides. Neurosci Lett 143:200–204

  33. 33.

    Maneuf YP, Nash JE, Crossman AR, Brotchie JM (1996) Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus. Eur J Pharmacol 308:161–164

  34. 34.

    Martyn CN, Illis LS, Thom J (1995) Nabilone in the treatment of multiple sclerosis. Lancet 345:579

  35. 35.

    Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561–564

  36. 36.

    Maurer M, Henn V, Dittrich A, Hofmann A (1990) Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial. Eur Arch Psychiatry Clin Neurosci 240:1-4

  37. 37.

    Mechoulam R, Hanu L (2001) The cannabinoids: an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection. Pain Res Manag 6:67–73

  38. 38.

    Meinck HM, Schonle PW, Conrad B (1989) Effect of cannabinoids on spasticity and ataxia in multiple sclerosis. J Neurol 236:120–122

  39. 39.

    Müller-Vahl KR, Koblenz A, Jobges M, Kolbe H, Emrich HM, Schneider U (2001) Influence of treatment of Tourette syndrome with delta9-tetrahydrocannabinol (delta9-THC) on neuropsychological performance. Pharmacopsychiatry 34:19–24

  40. 40.

    Müller-Vahl KR, Kolbe H, Schneider U, Emrich HM (1998) Cannabinoids: possible role in pathophysiology and therapy of Gilles de la Tourette syndrome. Acta Psychiatr Scand 98:502–506

  41. 41.

    Müller-Vahl KR, Kolbe H, Schneider U, Emrich HM (1999) Cannabis in movement disorders. Forsch Komplementarmed 6 [suppl 3]:23–27

  42. 42.

    Müller-Vahl KR, Schneider U, Emrich HM (1999) Nabilone increases choreatic movements in Huntington's disease. Mov Disord 14:1038–1040

  43. 43.

    Müller-Vahl KR, Schneider U, Koblenz A, Jobges M, Kolbe H, Daldrup T, Emrich HM (2002) Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry 35:57–61

  44. 44.

    Müller-Vahl KR, Schneider U, Kolbe H, Emrich HM (1999) Treatment of Tourette's syndrome with delta-9-tetrahydrocannabinol. Am J Psychiatry 156:495

  45. 45.

    Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61–65

  46. 46.

    Nadler V, Biegon A, Beit-Yannai E, Adamchik J, Shohami E (1995) 45Ca accumulation in rat brain after closed head injury; attenuation by the novel neuroprotective agent HU-211. Brain Res 685:1–11

  47. 47.

    Nagayama T, Sinor AD, Simon RP, Chen J, Graham SH, Jin K, Greenberg DA (1999) Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci 19:2987–2995

  48. 48.

    Ng SK, Brust JC, Hauser WA, Susser M (1990) Illicit drug use and the risk of new-onset seizures. Am J Epidemiol 132:47–57

  49. 49.

    Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R, Shohami E (2001) An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413:527–531

  50. 50.

    Pertwee RG (1988) The central neuropharmacology of psychotropic cannabinoids. Pharmacol Ther 36:189–261

  51. 51.

    Petro DJ (1980) Marihuana as a therapeutic agent for muscle spasm or spasticity. Psychosomatics 21:81, 85

  52. 52.

    Petro DJ, Ellenberger C jr (1981) Treatment of human spasticity with delta 9-tetrahydrocannabinol. J Clin Pharmacol 21:413S–416S

  53. 53.

    Rodriguez de Fonseca F, Del Arco I, Martin-Calderon JL, Gorriti MA, Navarro M (1998) Role of the endogenous cannabinoid system in the regulation of motor activity. Neurobiol Dis 5:483–501

  54. 54.

    Sandyk R, Snider SR, Consroe P, Elias SM (1986) Cannabidiol in dystonic movement disorders. Psychiatry Res 18:291

  55. 55.

    Schon F, Hart PE, Hodgson TL, Pambakian AL, Ruprah M, Williamson EM, Kennard C (1999) Suppression of pendular nystagmus by smoking cannabis in a patient with multiple sclerosis. Neurology 53:2209–2210

  56. 56.

    Shohami E, Gallily R, Mechoulam R, Bass R, Ben-Hur T (1997) Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant. J Neuroimmunol 72:169–177

  57. 57.

    Shohami E, Novikov M, Mechoulam R (1993) A nonpsychotropic cannabinoid, HU-211, has cerebroprotective effects after closed head injury in the rat. J Neurotrauma 10:109–119

  58. 58.

    Sieradzan KA, Fox SH, Hill M, Dick JP, Crossman AR, Brotchie JM (2001) Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology 57:2108–2111

  59. 59.

    Snider S, Consroe P (1984) Treatment of Meige's syndrome with cannabidiol. Neurology 34 [suppl]:147

  60. 60.

    Ungerleider JT, Andyrsiak T, Fairbanks L, Ellison GW, Myers LW (1987) Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse 7:39–50

  61. 61.

    Wirguin I, Mechoulam R, Breuer A, Schezen E, Weidenfeld J, Brenner T (1994) Suppression of experimental autoimmune encephalomyelitis by cannabinoids. Immunopharmacology 28:209–214

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to P. Schwenkreis.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Schwenkreis, P., Tegenthoff, M. Therapeutischer Einsatz von Cannabinoiden bei neurologischen Erkrankungen. Schmerz 17, 367–373 (2003). https://doi.org/10.1007/s00482-003-0240-z

Download citation

Schlüsselwörter

  • Cannabinoide
  • Multiple Sklerose
  • Spastik
  • Epilepsie
  • Neuroprotektion

Keywords

  • Cannabinoids
  • Multiple sclerosis
  • Spasticity
  • Epilepsy
  • Neuroprotection